Compare Organon & Co. Common Stock (OGN) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs SiTime Corporation — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while SiTime Corporation trades at $511.96 (market cap $17.43B). The key difference: SiTime Corporation is far larger — about 4.8× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while SiTime Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and SiTime Corporation for 18 Days on average.
| OGN | SITM | |
|---|---|---|
Market Cap | $3.62B | $17.43B |
Volume | 2,892,999 | 549,677 |
Sector | Health | Technology |
52-Week High | $13.81 | $901.60 |
52-Week Low | $5.70 | $252.76 |
Typical Hold Time | 0 Days | 18 Days |
Enterprise Value | $11.04B | $16.84B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
SITM trades at $579.66, up 1.68% today, showing strong momentum after recent earnings beats. The stock faces technical headwinds with bearish moving averages but benefits from unanimous analyst buy ratings and a $751.43 consensus price target. Recent Q2 2026 results showed 126.5% revenue growth to $157.43M and the company's first GAAP profit, driven by AI infrastructure demand and the Renesas acquisition.
The outlook remains positive with accelerating AI-driven growth, though high valuations (P/E 966.1) and negative 2025 net income ($-42.9M) pose risks. Institutional buying and strong Q3 guidance support upside potential, but investors should monitor execution on margin expansion and competitive pressures in the timing solutions market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
